Revenue Recognition

3 Months Ended

Apr. 03, 2021

Revenue from Contract with Customer [Abstract]

Revenue Recognition

REVENUE RECOGNITION

    Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

    We generated net sales in the following geographic locations(1) (in millions):

	Three Months Ended
	April 3, 2021		March 28, 2020
U.S.	$	611.3	$	670.7
Europe(2)	355.3		372.6
All other countries(3)	43.4		40.0
Total net sales	$	1,010.0	$	1,083.3

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $4.5 million and $3.8 million for the three months ended April 3, 2021, and March 28, 2020, respectively.

(3) Includes net sales generated primarily in Mexico, Australia and Canada.

Product Category

    The following is a summary of our net sales by category (in millions):

	Three Months Ended
	April 3, 2021		March 28, 2020
CSCA(1)
Upper respiratory	$	114.0	$	154.6
Digestive health	113.5		106.9
Pain and sleep-aids	92.4		120.4
Nutrition	92.0		102.2
Healthy lifestyle	75.5		85.8
Oral self-care	73.7		55.3
Skincare and personal hygiene	53.3		46.7
Vitamins, minerals, and supplements	7.8		6.4
Other CSCA(2)	18.3		22.3
Total CSCA	640.5		700.6
CSCI
Skincare and personal hygiene	107.0		94.7
Vitamins, minerals, and supplements	59.0		48.5
Healthy lifestyle	50.3		43.6
Pain and sleep-aids	49.0		46.8
Upper respiratory	42.9		84.1
Oral self-care	25.5		23.2
Digestive health	8.5		6.0
Other CSCI(3)	27.3		35.8
Total CSCI	369.5		382.7
Total net sales	$	1,010.0	$	1,083.3

(1) Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $63.1 million and $49.2 million for the three months ended April 3, 2021, and March 28, 2020, respectively.

    We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

    The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	April 3, 2021		December 31, 2020
Short-term contract assets	Prepaid expenses and other current assets	$	18.4	$	19.7